Progyny, Inc.: Board approved amendments to the bylaws consistent with the supermajority amendments, eliminating supermajority vote requirement to remove directors with cause and to amend the bylaws (effective 2026-05-21).
“In connection with the Charter Amendments, the Company’s Board of Directors (the “Board”) approved certain amendments to the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “Third Amended and Restated Bylaws”) consistent with the Supermajority Amendments. The Third Amended and Restated Bylaws amend Article IV, Section 21 and Article XIII, Section 47 to eliminate the supermajority vote requirement to remove directors with cause and to amend the bylaws, respectively. The Third Amended and Restated Bylaws became effective on May 21, 2026.”
Governance Changes
Progyny, Inc.: Stockholders approved amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements and eliminate the default supermajority voting requirement concerning certain business combinations (effective 2026-05-21).
“Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation. As further described in Proposals 4 and 5 of the Company’s definitive proxy statement filed on April 10, 2026 (the “Proxy Statement”), the Charter Amendments (a) eliminate certain supermajority voting requirements (the “Supermajority Amendments”), and (b) eliminate the default supermajority voting requirement concerning certain business combinations. The Charter Amendments became effective upon the filing of a Certificate of Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 21, 2026.”
Earnings Releases
Progyny, Inc. reported the three-month period ended March 31, 2026 results: revenue $328,504, net income $24,232, EPS $0.29.
“returned value to our investors by repurchasing 8.8 million shares.” First Quarter 2026 Highlights: (unaudited; in thousands, except per share amounts) 1Q 2026 1Q 2025 Revenue $328,504 $324,038 Gross Profit $83,071 $75,795 Gross Margin 25.3% 23.4% Net Income $24,232 $15,059 Net Income per Diluted Share 1 $0.29 $0.17 Adjusted Earnings per Diluted Share 2 $0.50”
Debt Financings
Progyny, Inc. incurred revolving credit of $200.0 million with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender at adjusted SOFR, or the alternate base rate, plus, in each case, an applicable mar maturing July 1, 2030.
“but not defined herein shall have the meanings assigned to such terms in the Credit Agreement. The Credit Agreement makes available to the Company a maximum aggregate amount of $200.0 million of revolving loan commitments, which may be drawn, subject to customary borrowing conditions, until maturity on July 1, 2030. Subject to certain conditions, the Company may at”
Dr. Fred E. Cohen departed as Director at Progyny, Inc..
“On April 9, 2025, Dr. Fred E. Cohen notified the Board of Directors of Progyny, Inc. (the “Company”) of his decision not to stand for reelection at the Company’s 2025 Annual Meeting of Stockholders.”
Debra Morris was appointed as Class III Director at Progyny, Inc..
“On January 10, 2025, the board of directors (the “Board”) of Progyny, Inc. (the “Company”) appointed Debra Morris to serve as a Class III director of the Company, effective January 16, 2025.”
Earnings Releases
Progyny, Inc. reported the three-month period ended March 31, 2024 results: revenue $278,078, net income $16,898, EPS $0.17.
“of February,” said Mark Livingston, Progyny’s Chief Financial Officer. First Quarter 2024 Highlights: (unaudited; in thousands, except per share amounts) 1Q 2024 1Q 2023 Revenue $278,078 $258,394 Gross Profit $62,406 $58,640 Gross Margin 22.4% 22.7% Net Income $16,898 $17,678 Net Income per Diluted Share 1 $0.17 $0.18 Adjusted Earnings Per Diluted Share 2 $0.39”
Earnings Releases
Progyny, Inc. reported the three- and twelve-month periods ended December 31, 2023 results: revenue $1,088.6 Million, net income $62,037, EPS $0.62. Guidance initiated.
“Progyny, Inc. Announces Fourth Quarter 2023 Results Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% Growth Achieves 49% Growth in Adjusted EBITDA to Record $187.1 Million Issues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint”
Earnings Releases
Progyny, Inc. reported financial results for the fiscal quarter and year ended December 31, 2023.
“On February 27, 2024, Progyny, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.